DK1951296T3 - Celleafledte virale vacciner med lave niveauer af restcelle-DNA - Google Patents

Celleafledte virale vacciner med lave niveauer af restcelle-DNA

Info

Publication number
DK1951296T3
DK1951296T3 DK06831855.9T DK06831855T DK1951296T3 DK 1951296 T3 DK1951296 T3 DK 1951296T3 DK 06831855 T DK06831855 T DK 06831855T DK 1951296 T3 DK1951296 T3 DK 1951296T3
Authority
DK
Denmark
Prior art keywords
cell
dna
cell culture
low levels
residual
Prior art date
Application number
DK06831855.9T
Other languages
English (en)
Other versions
DK1951296T4 (da
Inventor
Jens-Peter Gregersen
Holger Kost
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37969762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1951296(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Publication of DK1951296T3 publication Critical patent/DK1951296T3/da
Application granted granted Critical
Publication of DK1951296T4 publication Critical patent/DK1951296T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK06831855.9T 2005-11-01 2006-11-01 Celleafledte viral vacciner med lave niveauer af restcelle-DNA DK1951296T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73278605P 2005-11-01 2005-11-01
PCT/IB2006/003880 WO2007052163A2 (en) 2005-11-01 2006-11-01 Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment

Publications (2)

Publication Number Publication Date
DK1951296T3 true DK1951296T3 (da) 2011-03-28
DK1951296T4 DK1951296T4 (da) 2014-09-01

Family

ID=37969762

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06831855.9T DK1951296T4 (da) 2005-11-01 2006-11-01 Celleafledte viral vacciner med lave niveauer af restcelle-DNA

Country Status (19)

Country Link
US (2) US10655108B2 (da)
EP (3) EP2842572A1 (da)
JP (5) JP5602366B2 (da)
KR (1) KR20080081254A (da)
CN (2) CN104474543A (da)
AT (1) ATE494906T1 (da)
AU (2) AU2006310171B2 (da)
CA (1) CA2627971A1 (da)
CY (1) CY1111378T1 (da)
DE (1) DE602006019629D1 (da)
DK (1) DK1951296T4 (da)
EA (1) EA014062B1 (da)
ES (2) ES2525518T3 (da)
HK (2) HK1129837A1 (da)
NZ (1) NZ567817A (da)
PL (2) PL2301572T3 (da)
PT (1) PT2301572E (da)
SI (1) SI1951296T2 (da)
WO (1) WO2007052163A2 (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1951296T4 (da) * 2005-11-01 2014-09-01 Novartis Vaccines & Diagnostic Celleafledte viral vacciner med lave niveauer af restcelle-DNA
PL2478916T3 (pl) 2006-01-27 2020-11-16 Seqirus UK Limited Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
EA200970271A1 (ru) 2006-09-11 2010-02-26 Новартис Аг Получение вакцин против вируса гриппа без использования куриных эмбрионов
WO2009001217A2 (en) * 2007-06-27 2008-12-31 Novartis Ag Low-additive influenza vaccines
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
EP2889042A3 (en) 2008-03-18 2015-10-14 Novartis AG Improvements in preparation of influenza virus vaccine antigens
US20110217330A1 (en) * 2008-11-05 2011-09-08 Bruno Rene Andre Novel method
CA2763816A1 (en) 2009-04-27 2010-11-04 Novartis Ag Adjuvanted vaccines for protecting against influenza
NZ596432A (en) 2009-05-21 2013-05-31 Novartis Ag Reverse genetics using non-endogenous pol i promoters
CA2769673A1 (en) 2009-07-31 2011-02-03 Novartis Ag Reverse genetics systems
CN102648003B (zh) 2009-10-09 2016-01-13 儿童医疗中心有限公司 选择性裂解的全细胞疫苗
WO2011048560A1 (en) 2009-10-20 2011-04-28 Novartis Ag Improved reverse genetics methods for virus rescue
JP6200805B2 (ja) 2010-05-03 2017-09-20 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規な方法
BR112012028146A2 (pt) 2010-05-06 2015-09-15 Novartis Ag compostos de peróxido orgânico para inativação de microorganismos
EP2571520B1 (en) 2010-05-21 2018-04-04 Seqirus UK Limited Influenza virus reassortment method
CN103096921A (zh) 2010-06-01 2013-05-08 诺华有限公司 不用冻干疫苗抗原浓缩
CN102939104A (zh) 2010-06-01 2013-02-20 诺华有限公司 用冻干浓缩疫苗抗原
SG188947A1 (en) 2010-08-12 2013-06-28 Yisheng Biopharma Holdings Ltd Method for reducing dna impurities in viral compositions
EP2605792B1 (en) 2010-08-20 2014-12-10 Novartis AG Soluble needle arrays for delivery of influenza vaccines
AU2012221740B2 (en) 2011-02-25 2016-11-17 Novartis Ag Exogenous internal positive control
KR101900460B1 (ko) 2011-11-03 2018-11-08 센티넥스트 테라퓨틱스 에쓰디엔 비에이취디 인간 엔테로바이러스에 대한 백신
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
CN103608453B (zh) 2012-03-02 2018-07-24 思齐乐 流感病毒重配
WO2013131898A1 (en) 2012-03-06 2013-09-12 Crucell Holland B.V. Improved vaccination against influenza
CA2875752A1 (en) 2012-06-04 2013-12-12 Novartis Ag Improved safety testing
JP6421128B2 (ja) 2012-12-03 2018-11-07 ノバルティス アーゲー リアソータントインフルエンザａウイルス
CN105338999B (zh) 2013-03-13 2020-02-28 诺华股份有限公司 乙型流感病毒重配
CN105828835A (zh) 2013-05-10 2016-08-03 诺华股份有限公司 避免流感疫苗中的发作性嗜睡病风险
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
CA2914604A1 (en) 2013-06-06 2014-12-11 Novartis Ag Influenza virus reassortment
US10080792B2 (en) 2013-09-23 2018-09-25 Engen Bio, Inc. Influenza vaccine and therapy
CN104436157A (zh) 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
CN104513317B (zh) * 2013-09-30 2018-12-14 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
US20160287693A1 (en) * 2013-11-15 2016-10-06 Novartis Ag Removal of residual cell culture impurities
TWI688652B (zh) * 2014-05-28 2020-03-21 財團法人國家衛生研究院 作為對抗腸病毒感染之免疫原的病毒顆粒及其製造
BR112017028011A2 (pt) 2015-06-26 2018-08-28 Seqirus Uk Ltd vacinas de gripe correspondentes antigenicamente
CA2990745A1 (en) 2015-07-07 2017-01-12 Seqirus UK Limited Influenza potency assays
EP3184119A1 (en) * 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
CN109652384B (zh) * 2019-02-21 2021-10-26 昆明理工大学 一种体外培养戊型肝炎病毒的方法
IL293031A (en) 2019-11-18 2022-07-01 Seqirus Pty Ltd A method for producing reassortant influenza viruses
CN116407624B (zh) * 2023-04-14 2024-04-09 吉林省农业科学院(中国农业科技东北创新中心) 一种鸡传染性支气管炎细菌样颗粒疫苗的制备方法和应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4064232A (en) * 1974-01-14 1977-12-20 Sandoz Ltd. Process for isolating the immunogenic components of influenza viruses
CH589453A5 (da) * 1974-01-14 1977-07-15 Sandoz Ag
DE3788902T3 (de) 1986-06-17 2004-11-25 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Hepatitis-Delta-Diagnostika und Impfstoffe, ihre Herstellung und Verwendung.
GB8703696D0 (en) * 1987-02-18 1987-03-25 Oxford J S Influenza vaccine
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5010183A (en) 1989-07-07 1991-04-23 Macfarlane Donald E Process for purifying DNA and RNA using cationic detergents
JP2941859B2 (ja) 1989-09-20 1999-08-30 国立予防衛生研究所 Ｈａ蛋白の製造法
US5010112A (en) * 1989-12-01 1991-04-23 Massachusetts Institute Of Technology Method and apparatus for improving the insulating properties of closed cell foam
JP3108480B2 (ja) 1991-09-25 2000-11-13 松下電工株式会社 多重伝送システムの割込処理方法
US5824536A (en) 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
DE19612966B4 (de) * 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
AU755465C (en) * 1998-06-01 2004-01-29 Fidia Farmaceutici S.P.A. Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants
JP2000230931A (ja) 1998-12-07 2000-08-22 Katakura Industries Co Ltd 家畜インフルエンザウイルスに対する抗体の検出方法およびこれに用いるキット
HU229255B1 (en) * 1999-04-19 2013-10-28 Smithkline Beecham Biolog Vaccines
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
AR025750A1 (es) 1999-09-24 2002-12-11 Smithkline Beecham Biolog Vacunas
EP1103610A1 (en) 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
AU3241501A (en) 1999-12-08 2001-06-18 Crucell Holland B.V. Method of administering adenovirus
US6825036B2 (en) 2000-03-03 2004-11-30 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell
FR2808803B1 (fr) 2000-05-11 2004-12-10 Agronomique Inst Nat Rech Cellules es modifiees et gene specifique de cellules es
GB0024089D0 (en) * 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
WO2002067983A1 (en) 2001-02-23 2002-09-06 Glaxosmithkline Biologicals S.A. Novel vaccine
EP2269639B1 (en) * 2001-02-23 2018-11-28 GlaxoSmithKline Biologicals s.a. Influenza vaccine formulations for intradermal delivery
JP2004520144A (ja) 2001-04-27 2004-07-08 グラクソスミスクライン　バイオロジカルズ　ソシエテ　アノニム 新規ワクチン
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
DE10144903A1 (de) 2001-09-12 2003-03-27 Chiron Behring Gmbh & Co Vermehrung von Viren in Zellkultur
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
CN1678345A (zh) 2002-04-26 2005-10-05 米迪缪尼疫苗股份有限公司 制备流感病毒的多质粒系统
CA2501975A1 (en) 2002-12-20 2004-07-08 Crucell Holland B.V. Recombinant virus production for the manufacturing of vaccines
EP1618127B1 (en) * 2003-04-10 2014-12-10 Novartis Vaccines and Diagnostics, Inc. Immunogenic composition comprising a spike protein of the SARS coronavirus
KR100908757B1 (ko) 2003-05-28 2009-07-22 위스콘신 얼럼나이 리서어치 화운데이션 백신 및 유전자 요법을 위한 고 역가 재조합 인플루엔자바이러스
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
EP1780269B1 (en) 2004-02-23 2009-07-08 Crucell Holland B.V. Virus purification methods
WO2005113756A1 (en) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
AU2005245943A1 (en) 2004-05-20 2005-12-01 Id Biomedical Corporation Process for the production of an influenza vaccine
ES2432655T3 (es) * 2004-09-09 2013-12-04 Novartis Vaccines And Diagnostics Gmbh Reducción de riesgos iatrogénicos potenciales asociados con antígenos de vacunas
JP4031478B2 (ja) 2004-12-13 2008-01-09 プロテイン サイエンシーズ インフルエンザ血球凝集素多価ワクチンの製造方法
KR101260084B1 (ko) 2004-12-23 2013-05-03 메디뮨 엘엘씨 바이러스의 증식을 위한 비종양형성성 ｍｄｃｋ 세포주
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
DK1951296T4 (da) * 2005-11-01 2014-09-01 Novartis Vaccines & Diagnostic Celleafledte viral vacciner med lave niveauer af restcelle-DNA

Also Published As

Publication number Publication date
SI1951296T2 (sl) 2014-09-30
US11466257B2 (en) 2022-10-11
CN101365480A (zh) 2009-02-11
JP2020023557A (ja) 2020-02-13
US20090304729A1 (en) 2009-12-10
NZ567817A (en) 2012-01-12
SI1951296T1 (sl) 2011-04-29
EP2842572A1 (en) 2015-03-04
JP5602366B2 (ja) 2014-10-08
CN101365480B (zh) 2014-11-05
EP2301572A1 (en) 2011-03-30
JP2016185988A (ja) 2016-10-27
WO2007052163A3 (en) 2007-09-07
BRPI0618094A8 (pt) 2017-08-22
EA014062B1 (ru) 2010-08-30
DK1951296T4 (da) 2014-09-01
BRPI0618094A2 (pt) 2011-08-16
AU2011201968A1 (en) 2011-05-19
AU2006310171B2 (en) 2011-02-17
WO2007052163A2 (en) 2007-05-10
PL1951296T5 (pl) 2015-06-30
CA2627971A1 (en) 2007-05-10
AU2011201968B2 (en) 2014-08-28
DE602006019629D1 (de) 2011-02-24
EP1951296B1 (en) 2011-01-12
CY1111378T1 (el) 2015-08-05
EA200801221A1 (ru) 2008-10-30
JP2009513694A (ja) 2009-04-02
KR20080081254A (ko) 2008-09-09
US20200377864A1 (en) 2020-12-03
ES2359214T3 (es) 2011-05-19
ES2525518T3 (es) 2014-12-26
JP2014198726A (ja) 2014-10-23
US10655108B2 (en) 2020-05-19
JP6639077B2 (ja) 2020-02-05
JP2011256209A (ja) 2011-12-22
PL1951296T3 (pl) 2011-09-30
ES2359214T5 (es) 2014-10-08
EP1951296B2 (en) 2014-07-23
PL2301572T3 (pl) 2015-02-27
HK1207828A1 (en) 2016-02-12
EP2301572B1 (en) 2014-09-10
AU2006310171A1 (en) 2007-05-10
CN104474543A (zh) 2015-04-01
ATE494906T1 (de) 2011-01-15
HK1129837A1 (en) 2009-12-11
EP1951296A2 (en) 2008-08-06
JP7049761B2 (ja) 2022-04-07
PT2301572E (pt) 2014-12-22

Similar Documents

Publication Publication Date Title
DK1951296T4 (da) Celleafledte viral vacciner med lave niveauer af restcelle-DNA
WO2007095318A3 (en) Influenza antigens, vaccine compositions, and related methods
MX2012001592A (es) Composicion para el tratamiento de la infección del virus de la hepatitis b.
CY1114356T1 (el) Αναστολεις του ιου της ηπατιτιδας c
EA201390538A1 (ru) Противовирусные соединения
MX2012000035A (es) Antigenos de virus de sincicio respiratorio recombinantes.
EA200870304A1 (ru) Псевдоинфекционный флавивирус и его применение
WO2007024941A3 (en) Polyvalent vaccine
EA201591888A1 (ru) Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
WO2012061815A3 (en) RABIES GLYCOPROTEIN VIRUS-LIKE PARTICLES (VLPs)
WO2010019262A3 (en) Polyvalent vaccine
WO2007095320A3 (en) Hpv antigens, vaccine compositions, and related methods
AR061894A1 (es) Vacunas para malaria
UA108902C2 (uk) Вірус північноамериканського репродуктивного та респіраторного синдрому свиней (prrs) та його застосування
WO2010001409A3 (en) Vaccine composition useful for hpv and hepatitis b infections and a method for preparing the same
WO2010095041A3 (en) Compositions, methods, and kits for treating influenza viral infections
ME01140B (me) Virus goveđe virusne dijareje s modifikovanim erns proteinom
EP1989316A4 (en) METHOD FOR THE PRODUCTION OF RECOMBINANT VIRUS, DNA CONSTRUCTS, RECOMBINANT VIRUS AND VACCINE COMPOSITIONS
PH12015501378B1 (en) Porcine parvovirus 5a, methods of use and vaccine
PH12015501721A1 (en) Porcine parvovirus 5b, methods of use and vaccine
WO2008064072A3 (en) Anti-tsg101 antibodies and their uses for treatment of viral infections
TW200531701A (en) Method of vaccination against testicular BVDV infection
WO2007028985A3 (en) Adjuvanted vaccine
WO2007104263A8 (zh) 一种乙型肝炎病毒疫苗增效蛋白及其基因
TR201905336T4 (tr) Rekombinant rsv antijenleri.